The most direct approach to therapy for A1-PI deficiency in patients has been to partially replace the missing protease inhibitor by intravenous infusion and thus, attempt to ameliorate the imbalance in the anti-neutrophil elastase protection of the lower respiratory tract.
The only FDA-approved treatment specifically for Alpha-1 deficiency is augmentation therapy. Augmentation therapy increases and maintains serum levels and lung epithelial lining fluid (ELF) levels of A1-PI.
Learn more about Alpha-1 Augmentation Therapy.